目的 探讨不同剂量辛伐他汀治疗慢性阻塞性肺疾病（COPD）的疗效、安全性及对肺功能的影响。方法 选取2015年7月—2016年1月于榆林市第二医院接受治疗的COPD患者192例作为研究对象，采用随机数字表法分为A、B两组，各96例。A组患者使用辛伐他汀剂量为40 mg/d，B组患者使用剂量为20 mg/d。两组均进行为期6个月的治疗。比较两组患者临床疗效、肺功能[主要指标包括第一秒用力呼气容积（FEV1）、第一秒用力呼气容积占预计值百分比（FEV1%）、用力肺活量（FVC）]、生活质量及安全性。结果 A组治疗1个月时总有效率（82.29%）与B组（70.83%）相比差异不明显；治疗3个月（89.85% vs 77.08%）及6个月时（93.75% vs 84.38%）均明显高于B组，差异有统计学意义（P<0.05）。治疗1个月时两组肺功能各指标差异不明显，治疗3个月及6个月时A组各指标均明显优于B组，差异有统计学意义（P<0.05）。治疗后两组生活质量均得到明显好转，A组患者生活质量明显优于B组，差异有统计学意义（P<0.05）。两组患者用药安全性比较无显著差异。结论 大剂量辛伐他汀治疗COPD疗效及安全性良好，可显著改善肺功能并提高患者生活质量，值得临床推广应用。

Objective To explore the clinical effect, safety and influence on pulmonary function of different doses of simvastatin in treatment of COPD.Methods Totally 192 COPD patients accepted in The Second Hospital of Yulin from July 2015 to January 2016 were selected and randomly divided into groups A and B with 96 cases in each group. Patients in group A were given 40 mg/d simvastatin, and patients in group B were given 20 mg/d simvastatin. Then the clinical effect, pulmonary function, life quality and safety of two groups were compared.Results The total effective rates after 1 month treatment of group A and group B were 82.29% and 70.83% respectively, which had no difference between two groups. The total effective rates of group A after 3 months treatment (89.95% vs 77.08%) and 6 months treatment (93.75% vs 84.38%) were higher than that of group B, and the differences were significantly (P<0.05). The indexes of pulmonary function after 1 month treatment of two groups had no difference. The indexes of pulmonary function after 3 months and 6 months of treatment of group A were obviously better than those of group B, and the differences were significantly (P<0.05). The life quality of group A was better than group B, and the differences were significantly (P<0.05). The safety between two groups had no difference.Conclusion Simvastatin (40 mg/d) has good effect and safety in the treatment of COPD, which can improve the lung function and life quality and is worthy of clinical applications.